Anzeige
Mehr »
Donnerstag, 18.12.2025 - Börsentäglich über 12.000 News
Das ist kein Gold-Boom, das ist ein Systembruch - und er hat gerade erst begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PYCU | ISIN: US46062X3035 | Ticker-Symbol: PF42
München
17.12.25 | 08:00
1,130 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
INTERPACE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
INTERPACE BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8851,29017.12.

Aktuelle News zur INTERPACE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.12.INTERPACE BIOSCIENCES, INC. - 8-K, Current Report1
03.12.Interpace Biosciences, Inc.: Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners36PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) ("Interpace" or the "Company") today announced that it has fully repaid its outstanding term loan facility...
► Artikel lesen
13.11.Interpace Biosciences GAAP EPS of $0.04, revenue of $8.76M1
12.11.Interpace Biosciences, Inc.: Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results129-Q3 Revenue of $8.8 million -Q3 Cash Collections of $10.0 million -Q3 Thyroid test volume up 12% year-over-year to record levels -Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels...
► Artikel lesen
INTERPACE BIOSCIENCES Aktie jetzt für 0€ handeln
12.11.INTERPACE BIOSCIENCES, INC. - 10-Q, Quarterly Report1
15.09.Interpace Biosciences, Inc.: Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association (ATA) Annual Meeting3
08.08.INTERPACE BIOSCIENCES, INC. - 8-K, Current Report1
07.08.Interpace Biosciences GAAP EPS of -$0.14, revenue of $9.2M1
07.08.INTERPACE BIOSCIENCES, INC. - 10-Q, Quarterly Report1
24.04.Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk231Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace"...
► Artikel lesen
31.01.Interpace Biosciences, Inc.: Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results317Q4 and FY Test volume increase 21% and 17% year-over-year -Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences...
► Artikel lesen
27.01.Interpace Biosciences, Inc.: PancraGEN Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan263PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX: IDXG) today announced notification that the...
► Artikel lesen
10.01.Interpace Biosciences, Inc.: Effective 02/07/2025, Interpace Diagnostics to No Longer Offer PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk246PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX: IDXG) today responded to the final Local Coverage...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1